Paneling human thyroid cancer cell lines for candidate proteins for targeted anti-angiogenic therapy

Journal of Cellular Biochemistry

Volumn 98, Issue 4, 2006, Pages 954-965

  Hoffmann, Sebastian ^a   Wunderlich, Anette ^a   Celik, Ilhan ^a   Maschuw, Katja ^a   Hassan, Iyad ^a   Hofbauer, Lorenz C ^a   Zielke, Andreas ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

aaaTIII; Angiogenesis; Angiostatin; Endostatin; FGF 2; Thyroid cancer; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 2; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; VASCULOTROPIN;

ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; ENDOTHELIUM CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MITOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN TARGETING; THYROID CANCER; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; CARCINOMA; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; THYROID NEOPLASMS;

EID: 33745618180     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20832     Document Type: Article

References (45)

1. Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ, Debus J, Ansorge W, Folkman J, Hlatky L, Huber PE. 2004. Endostatin's antiangiogenic signaling network. Mol Cell 13:649-663.
2. Ain KB. 1999. Anaplastic thyroid carcinoma: A therapeutic challenge. Semin Surg Oncol 16:64-69.
3. Barth PJ, Weingärtner K, Köhler HH, Bittinger A. 1996. Assessment of the vascularization in prostatic carcinoma: A morphometric investigation. Hum Pathol 27:1306-1310.
4. Bauer AJ, Terrell R, Doniparthi NK, Patel A, Tuttle RM, Saji M, Ringel MD, Francis GL. 2002. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid 12:953-961.
5. Blagosklonny MV. 2001. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review). Int J Oncol 19:257-262.
6. Cao Y, Xue L. 2004a. Angiostatin. Semin Thromb Hemost 30:83-93.
7. Cao Y. 2004b. Antiangiogenic cancer therapy. Semin Cancer Biol 14:139-145.
8. Fenton C, Patel A, Dinauer C, Robie DK, Tuttle RM, Francis GL. 2000. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 10:349-357.
9. Folkman J. 1990. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6.
10. Folkman J. 2002. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15-18.
11. Hanahan D, Folkmann J. 1996. Patterns and emerging mechanisms of the angiogenetic switch during tumorigenesis. Cell 86:353-364.
12. Heldin NE, Gustavsson B, Claesson-Welsh L, Hammacher A, Mark J, Heldin CH, Westermark B. 1988. Aberrant expression of receptors for platelet-derived growth factor in an anaplastic thyroid carcinoma cell line. Proc Natl Acad Sci USA 85:9302-9306.
13. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL. 2002. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20:3792-3803.
14. Hoffmann S, Hofbauer LC, Scharrenbach V, Wunderlich A, Hassan I, Lingelbach S, Zielke A. 2004. TSH-induced production of VEGF in thyroid cancer cells in vitro: Evaluation of TSH-signal transduction and of angiogenesis-stimulating growth factors. J Clin Endocrinol Metab 89:6139-6145.
15. Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, Coomber BL, Rak J. 2001. Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches. Cancer Metastasis Rev 20:79-86.
16. Kisker O, Onizuka S, Banyard J, Komiyama T, Becker CM, Achilles EG, Barnes CM, O'Reilly MS, Folkman J, Pirie-Shepherd SR. 2001. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res 61:7298-7304.
17. Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plenat F, Leclere J, Duprez A, Weryha G. 2001. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 86:656-658.
18. Kurebayashi J, Otsuki T, Tanaka K, Yamamoto Y, Moriya T, Sonoo H. 2003. Medroxyprogesterone acetate decreases secretion of interleukin-6 and parathyroid hormone-related protein in a new anaplastic thyroid cancer cell line, KTC-2. Thyroid 13:249-258.
19. Lennard CM, Patel A, Wilson J, Reinhardt B, Tuman C, Fenton C, Blair E, Francis GL, Tuttle RM. 2001. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 129:552-558.
20. McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, van Heerden JA, Goellner JR. 2001. Anaplastic thyroid carcinoma: A 50-year experience at a single institution. Surgery 130:1028-1034.
21. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moss M, Lane WS, Cao Y, Sage EH, Folkman J. 1994. Angisostatin: A novel angigogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328.
22. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane ES, Flynn E, Birkhaed JR, Olsen BR, Folkman J. 1997. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285.
23. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. 1999. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285:1926-1928.
24. Pasieka Z, Stepien H, Komorowski J, Kolomecki K, Kuzdak K. 2003. Evaluation of the levels of FGF-2, VEGF, sICAM-1, and sVCAM-1 in serum of patients with thyroid cancer. Recent Results Cancer Res 162:189-194.
25. Pawelec G. 2004. Tumour escape: Antitumour effectors too much of a good thing? Cancer Immunol Immunother 53:262-274.
26. Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, Ostman A. 2002. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62:5476-5484.
27. Podtcheko A, Ohtsuru A, Tsuda S, Namba H, Saenko V, Nakashima M, Mitsutake N, Kanda S, Kurebayashi J, Yamashita S. 2003. The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 88:1889-1896.
28. Prox D, Becker C, Pirie-Shepherd SR, Celik I, Folkman J, Kisker O. 2003. Treatment of human pancreatic cancer in mice with angiogenic inhibitors. World J Surg 27:405-411.
29. Ramsden JD, Yarram S, Mathews E, Watkinson JC, Eggo MC. 2002. Thyroid follicular cells secrete plasminogen activators and can form angiostatin from plasminogen. J Endocrinol 173:475-481.
30. Schoenberger J, Grimm D, Kossmehl P, Infanger M, Kurth E, Eilles C. 2004. Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: An animal study. Endocrinology 145:1031-1038.
31. Schuch G, Kisker O, Atala A, Soker S. 2002. Pancreatic tumor growth is regulated by the balance between positive and negative modulators of angiogenesis. Angiogenesis 5:181-190.
32. Sherman SI. 2003. Thyroid carcinoma. Lancet 361:501-511.
33. Soh EY, Duh QY, Sobhi SA, Young DM, Epstein HD, Wong MG, Garcia YK, Min YD, Grossman RF, Siperstein AE, Clark OH. 1997. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 82(11):3741-3747.
34. Soh EY, Sobhi SA, Wong MG, Meng GM, Siperstein AE, Clark OH, Duh QY. 2000a. Thyroid-stimulationg hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. Surgery 120:944-947.
35. Soh EY, Eigelberger MS, Kim KJ, Wong MG, Young DM, Clark OH, Duh QY. 2000b. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo. Surgery 128:1059-1065.
36. Trojan L, Thomas D, Knoll T, Grobholz R, Alken P, Michel MS. 2004. Expression of pro-angiogenic growth factors VEGF, EGF and FGF-2 and their topographical relation to neovascularisation in prostate cancer. Urol Res 32:97-103.
37. Tsuboi S, Nouso K, Tomono Y, Nagamori S, Naito I, Watanabe T, Manabe K, Ohmori H, Nakatsukasa H, Miyazaki M, Higashi T, Shiratori Y, Namba M, Ninomiya Y. 2004. Anti-endostatin monoclonal antibody enhances growth of human hepatocellular carcinoma cells by inhibiting activity of endostatin secreted by the transplanted cells in nude mice. Int J Oncol 25:1267-1271.
38. Turner HE, Harris AL, Melmed S, Wass JA. 2003. Angiogenesis in endocrine tumors. Endocr Rev 24:600-632.
39. Vesely D, Astl J, Matucha P, Sterzl I, Betka J. 2003. Serum levels of angiogenic growth factors in patients with thyroid gland tumors and parathyroid adenoma. Neuro Endocrinol Lett 24:417-419.
40. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, Fedele M, Ippolito P, Chiappetta G, Botti G. 1995. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PIGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11:1569-1579.
41. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS. 2001. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 61:5090-5101.
42. Xu G, Pan J, Martin C, Yeung SC. 2001. Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab 86:1769-1777.
43. Ye C, Feng C, Wang S, Liu X, Lin Y, Li M. 2002. Antiangiogenic and antitumor effects of endostatin on follicular thyroid carcinoma. Endocrinology 143:3522-3528.
44. Zielke A, Bresalier RS, Siperstein AE, Clark OH, Rothmund M, Duh QY. 1998. A unique allogenic model of metastatic pheochromocytoma: PC12 rat pheochromocytoma xenografts to nude mice and establishment of metastases-derived PC12 variants. Clin Exp Metastasis 16:341-352.
45. Zielke A, Hoffmann S, Plaul U, Duh Q-Y, Clark OH, Rothmund M. 1999. Pleiotropic effects of thyroid stimulating hormone in differentiated thyroid cancer: Studies on proliferation, thyroglobin secretion, adhesion, migration and invasion. Exp Clin Endocrinol Diabetes 107:361-369.